# **Special Issue**

# The Role of Molecular Docking in the Design of Targeted Therapeutic Entities and Nanomaterials

## Message from the Guest Editors

Molecular docking has become a useful computational technique for aiding in drug design by providing insights on interactions and dynamics of molecules and nanomaterials within biological systems. The docking of therapeutic entities and/or nanomaterials enables the prediction of preferred orientations and binding capacities of the developed therapeutics and nanostructures with the target site, thus, providing the capability to predict and achieve superior pharmacological activities. Given the wide variety of pharmacological targets and biomedical applications of nanoconstructs, this research area has received considerable interest. Accordingly, authors are invited to submit high-quality research articles regarding topics such as, but not limited to, molecular docking studies for designing novel compounds and/or nanomaterials for various biomedical applications. Review submissions highlighting the latest advances in the study of the design and biological interactions of novel active entities (i.e., active molecules and nanomaterials) with pharmacological targets are also encouraged.

## **Guest Editors**

## Prof. Mahmoud Elsabahy

- 1. Department of Chemistry, Texas A&M University, College Station, TX, USA
- 2. Science Academy, Badr University in Cairo, Badr City, Egypt

## Dr. Noura G. Eissa

- 1. Department of Pharmaceutics, Faculty of Pharmacy, Zagazig University, Zagazig 44519, Egypt
- 2. Science Academy, Badr University in Cairo, Badr City, Cairo 11829, Egypt

## Deadline for manuscript submissions

closed (25 March 2025)



# **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/146571

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceutica**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals*.

We hope to handle your contribution to *Pharmaceuticals* soon.

## Editor-in-Chief

## Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

## **Author Benefits**

## Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

## Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

